Topical Immunomodulatory Drugs for Dry Eye: Cyclosporine (Restasis and Cequa)
What Are Topical Immunomodulatory Drugs for Dry Eye
Dry eye disease often involves chronic inflammation that reduces your eyes' ability to produce healthy, consistent tears. When over-the-counter drops are no longer enough, topical immunomodulatory medications like cyclosporine can address the root cause of this inflammation rather than simply replacing moisture on the surface. According to the TFOS DEWS II Management and Therapy Report, topical anti-inflammatory therapy such as cyclosporine is recommended as a cornerstone of moderate to severe dry eye disease management (TFOS DEWS II, 2017). At Greenwich Ophthalmology Associates, our dry eye specialists help patients throughout the greater NY/CT region determine whether prescription cyclosporine eye drops are the right next step in their treatment plan.
In many patients with dry eye, overactive immune cells called T-cells infiltrate the tear glands and ocular surface, releasing inflammatory signals that damage the tissues responsible for producing tears. This cycle of inflammation and tissue damage leads to decreased tear production, an unstable tear film, and the persistent discomfort associated with dry eye disease. Without addressing this underlying inflammation, symptom relief from lubricating drops alone is often incomplete.
Cyclosporine is a calcineurin inhibitor, a type of immunosuppressant that works at the cellular level to interrupt the inflammatory cycle. When applied topically to the eye, cyclosporine penetrates T-cells and blocks the activation signals that drive inflammation. Over time, this allows the lacrimal glands to recover and resume healthier tear production.
Two FDA-approved brand-name cyclosporine eye drops are currently available for dry eye treatment. Restasis contains 0.05% cyclosporine in an oil-in-water emulsion, while Cequa delivers 0.09% cyclosporine using a newer nanomicellar technology. Both are used twice daily and are designed for long-term management of chronic dry eye. Our dry eye specialists can help you understand how each option may fit your specific needs, and you can learn more about how these drops compare to other prescription dry eye medications.
How Cyclosporine (Restasis) Treats Dry Eye
Restasis was the first FDA-approved topical cyclosporine formulation for dry eye and remains one of the most widely prescribed treatments. Restasis is formulated as a 0.05% cyclosporine ophthalmic emulsion. It is available in single-use vials and multi-dose bottles, with a generic version currently offered for the single-use vials. Each dose is instilled as one drop in each eye, twice per day.
Once applied, Restasis suppresses the T-cell mediated inflammatory response on the ocular surface and within the lacrimal glands. By blocking the release of pro-inflammatory cytokines, the medication allows damaged tear-producing tissues to gradually heal. Clinical studies have confirmed that Restasis improves objective measures of dry eye, including Schirmer scores, tear film breakup time, and corneal surface staining. For a deeper look at what to expect when starting this medication, visit our guide on how Restasis works and what to expect.
Restasis is indicated for patients whose dry eye is associated with ocular surface inflammation and reduced tear production. It is approved for use in patients 16 years of age and older. Restasis is not intended for use while wearing contact lenses, and lenses should be removed before instilling the drops. Patients with active eye infections should resolve those infections before beginning treatment. Because dry eye disease can present differently from person to person, a thorough evaluation of the tear film, ocular surface, and meibomian glands helps ensure that treatment targets the specific underlying cause rather than masking symptoms temporarily.
What Is Cequa and How Does It Differ from Restasis
Cequa is a newer cyclosporine formulation that uses a different delivery technology and a higher concentration of the active ingredient. Unlike the emulsion base used in Restasis, Cequa uses nanomicellar technology to deliver cyclosporine. Nanomicelles are extremely small molecular structures that improve the solubility of cyclosporine in an aqueous solution. This technology is designed to enhance penetration of the medication into the tissues of the ocular surface. At Greenwich Ophthalmology Associates, our coordinated care model between a board-certified ophthalmologist and a residency-trained optometrist with specialized dry eye expertise allows us to evaluate your condition from multiple clinical perspectives and develop a targeted treatment plan.
Cequa contains 0.09% cyclosporine, nearly twice the concentration found in Restasis. Comparative studies have shown that the nanomicellar formulation can achieve higher cyclosporine concentrations in the conjunctiva and sclera compared to the traditional emulsion. This improved tissue penetration may translate to faster onset of therapeutic effects for some patients, though individual responses vary. Understanding the root cause of your symptoms is a critical first step, because the most effective treatment for dry eye depends on whether the condition involves insufficient tear production, excessive tear evaporation, or a combination of both mechanisms.
The choice between Restasis and Cequa depends on several factors, including your response to previous treatments, tolerance of side effects, insurance coverage, and your eye care provider's clinical judgment. Some patients who do not respond adequately to one formulation may benefit from switching to the other. Our dry eye specialists evaluate your tear film quality, inflammation levels, and treatment history to recommend the most appropriate option. Many patients find that dry eye symptoms fluctuate with environmental factors such as humidity levels, screen time, air conditioning, and seasonal allergens, which is why ongoing monitoring and periodic reassessment of your treatment plan can help maintain lasting comfort.
How Long Does It Take for Cyclosporine to Work
One of the most important things to understand about cyclosporine eye drops is that they are not fast-acting symptom relievers. Most patients using Restasis begin to notice improvements in comfort and tear production within three to six months of consistent, twice-daily use. Some patients may experience mild improvements earlier, but the full therapeutic benefit typically requires at least six months. Our practice serves patients throughout the greater New York and Connecticut region, and we understand that living with chronic eye discomfort can affect your ability to work, read, drive, and enjoy everyday activities, which is why we take a comprehensive and individualized approach to care.
Cequa's nanomicellar delivery system and higher cyclosporine concentration may lead to a somewhat faster onset of improvement for some patients, with early changes sometimes noticeable within the first few weeks to months. However, as with Restasis, maximum benefit develops gradually. Patients should plan on using Cequa consistently for several months before evaluating its full effectiveness. Identifying contributing factors such as medications, systemic health conditions, hormonal changes, and environmental exposures is an important part of the evaluation process, because addressing these influences alongside direct ocular surface treatment often leads to more sustained improvement.
Cyclosporine works by progressively reducing inflammation and allowing the ocular surface to heal. Missing doses or stopping treatment prematurely can interrupt this recovery process and delay results. Our dry eye specialists often recommend pairing cyclosporine with supportive therapies such as preservative-free artificial tears during the initial months to help manage symptoms while the medication takes effect.
Frequently Asked Questions
The most common side effect of both Restasis and Cequa is a temporary burning or stinging sensation upon instillation, which affects roughly 17% of patients. Other possible side effects include mild eye redness, watery eyes, blurred vision, and the feeling of something in the eye. These effects are generally mild and tend to diminish with continued use. No vision-threatening side effects have been reported in clinical studies.
Cyclosporine eye drops are typically recommended for patients with moderate to severe dry eye disease that has an inflammatory component, particularly when artificial tears alone have not provided sufficient relief. Patients with autoimmune conditions such as Sjogren syndrome, those with chronic ocular surface inflammation, and individuals whose dry eye significantly affects daily activities may be strong candidates.
Yes. Many patients use artificial tears alongside their prescription cyclosporine drops for additional comfort, especially during the initial months before the medication reaches full effectiveness. To avoid diluting the prescription drop, wait at least 15 minutes between instilling your cyclosporine and any other eye drop. Preservative-free artificial tears are generally preferred.
Artificial tears provide temporary moisture and lubrication to the ocular surface but do not treat the underlying cause of dry eye. Cyclosporine drops, by contrast, target the inflammatory process that reduces your body's natural tear production. Think of artificial tears as a short-term comfort measure and immunomodulatory drops as a long-term treatment aimed at helping your eyes produce better tears on their own.
Coverage varies by insurance plan. Restasis has been available longer and now has a generic version, which may make it more affordable or easier to get covered. Cequa, as a newer branded medication, may require prior authorization from some insurers. Most manufacturers offer patient assistance programs or copay cards that can reduce out-of-pocket costs.
What our Patients say
4.8
Reviews
(3,408)